Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Short Communication

Cyclosporin A Treatment for Membranoproliferative Glomerulonephritis Type II

Kiyomasu T.a · Shibata M.a · Kurosu H.a · Shiraishi K.a · Hashimoto H.a · Hayashidera T.a · Akiyama Y.a · Takeda N.b

Author affiliations

Departments of Pediatrics,aKyoto National Hospital, Kyoto, and bKurashiki Central Hospital, Okayama, Japan

Related Articles for ""

Nephron 2002;91:509–511

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Short Communication

Published online: July 01, 2002
Issue release date: July 2002

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Abstract

A nephrotic patient with membranoproliferative glomerulonephritis type II (MPGN II) was treated with cyclosporin A (CSA) and alternate-day low-dose prednisolone. This patient developed the nephrotic syndrome twice. The second episode of the nephrotic syndrome was steroid resistant, and therefore this patient was treated with a CSA regimen. During treatments with alternate-day low-dose prednisolone and CSA, this patient recovered from the nephrotic syndrome. We conclude that CSA therapy may be effective for patients with the steroid-resistant nephrotic syndrome caused by MPGN II.

© 2002 S. Karger AG, Basel


References

  1. Berger J, Galle P: Alteration singuilière des membranes basales du rein. J Urol Nephrol 1963;68:116–122.
    External Resources
  2. McEnery PT, McAdams AJ: Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): Observation in six children. Am J Kidney Dis 1988;12:138–146.
    External Resources
  3. Grupe WE: Minimal change disease. Semin Nephrol 1982;2:241–252.
  4. Faedda R, Satta A, Tanda F, Ririsi M, Bartoli E: Immunosuppressive treatments of membranoproliferative glomerulonephritis. Nephron 1992;67:59–65.
  5. Tejani A: Cyclosporin-induced remission of relapsing nephrotic syndrome in children (abstract). Kidney Int 1986;29:206.
  6. West CD, McAdams AJ, McConville JM, Davis NC, Holland NH: Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis: Clinical and pathological characteristics. J Pediatr 1965;67:1089–1112.
  7. Somers M, Kertesz S, Rosen S, Herrin J, Colvin R, Palacios de Carreta N, Kim M: Non-nephrotic children with membranoproliferative glomerulonephritis: Are steroids indicated? Pediatr Nephrol 1995;9:140–144.
  8. Schwertz R, de Jong R, Gretz N, Kirschfink M, Anderes D, Scarer K, Arbeitsgemeinschaft Pädiatrische Nephrologie: Outcome of idiopathic membranoproliferative glomerulonephritis in children. Acta Paediatr 1996;85:308–312.
    External Resources
  9. Singh A, Tejani C, Tejani A: One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 1999;13:26–32.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Short Communication

Published online: July 01, 2002
Issue release date: July 2002

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.